Carmat TAH Early Feasibility Study
Carmat Total Artificial Heart Early Feasibility Study
Sponsor: Carmat SAS
Suspended
Occurrence of a quality issue affecting some of its prostheses
Listed as NCT04117295, this NA trial focuses on End-stage Heart Failure and remains suspended. Sponsored by Carmat SAS, it has been updated 16 times since 2021, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
16 versions recorded-
Feb 2026 — Present [monthly]
Suspended NA
-
Feb 2025 — Feb 2026 [monthly]
Suspended NA
-
Sep 2024 — Feb 2025 [monthly]
Suspended NA
-
Jul 2024 — Sep 2024 [monthly]
Suspended NA
-
Feb 2024 — Jul 2024 [monthly]
Suspended NA
▶ Show 11 earlier versions
-
Sep 2022 — Feb 2024 [monthly]
Suspended NA
-
Feb 2022 — Sep 2022 [monthly]
Suspended NA
Status: Recruiting → Suspended
-
Sep 2021 — Feb 2022 [monthly]
Recruiting NA
-
Jun 2021 — Sep 2021 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — Jun 2021 [monthly]
Not Yet Recruiting NA
-
Mar 2021 — Apr 2021 [monthly]
Not Yet Recruiting NA
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting NA
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting NA
-
May 2020 — Dec 2020 [monthly]
Not Yet Recruiting NA
-
Feb 2020 — May 2020 [monthly]
Not Yet Recruiting NA
-
Nov 2019 — Feb 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Carmat SAS
For direct contact, visit the study record on ClinicalTrials.gov .